Back to Search
Start Over
Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
- Source :
-
Haematologica [Haematologica] 2005 Jan; Vol. 90 (1), pp. 131-3. - Publication Year :
- 2005
-
Abstract
- We studied 94 clinically heterogeneous chronic myeloid leukemia (CML) patients and found that the duration of treatment with interferon-alpha (IFN-alpha) prior to imatinib therapy may not improve response to imatinib for patients in chronic phase but a shorter period between CML diagnosis and the initiation of imatinib is predictive for a better molecular response to therapy (p<0.05).
- Subjects :
- Adolescent
Adult
Aged
Benzamides
Drug Administration Schedule
Female
Humans
Imatinib Mesylate
Interferon-alpha administration & dosage
Male
Middle Aged
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Piperazines therapeutic use
Pyrimidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 90
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Editorial & Opinion
- Accession number :
- 15642682